Trial · NCT01620216
Adverse events273
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 273
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acute kidney injury | Renal and urinary disorders | Group I (Dasatinib) | 0 | 4 | 0 |
| other | Acute kidney injury | Renal and urinary disorders | Group II (Sunitinib Malate) | 0 | 2 | 0 |
| other | Acute kidney injury | Renal and urinary disorders | Group III (Sorafenib Tosylate) | 1 | 6 | 1 |
| other | Acute kidney injury | Renal and urinary disorders | Group IV (Ponatinib Hydrochloride) | 0 | ||
| other | Acute kidney injury | Renal and urinary disorders | Group V (Pacritinib) | 0 | ||
| other | Acute kidney injury | Renal and urinary disorders | Group VI (Ruxolitinib) | 0 | ||
| other | Acute kidney injury | Renal and urinary disorders | Group VII (Idelalisib) | 0 | ||
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group I (Dasatinib) | 1 | 4 | 1 |
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group II (Sunitinib Malate) | 0 | 2 | 0 |
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group III (Sorafenib Tosylate) | 0 | 6 | 0 |
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group IV (Ponatinib Hydrochloride) | 0 | ||
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group V (Pacritinib) | 0 | ||
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group VI (Ruxolitinib) | 0 | ||
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Group VII (Idelalisib) | 0 | ||
| other | Anemia | Blood and lymphatic system disorders | Group I (Dasatinib) | 0 | 4 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Group II (Sunitinib Malate) | 0 | 2 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Group III (Sorafenib Tosylate) | 2 | 6 | 2 |
| other | Anemia | Blood and lymphatic system disorders | Group IV (Ponatinib Hydrochloride) | 0 | ||
| other | Anemia | Blood and lymphatic system disorders | Group V (Pacritinib) | 0 | ||
| other | Anemia | Blood and lymphatic system disorders | Group VI (Ruxolitinib) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01620216/events